The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Anti-Vascular Endothelial Growth Factor Therapeutics Market Across 2026–2030?
The anti-vascular endothelial growth factor therapeutics market has experienced slight expansion in recent years. This market is projected to expand from $12.17 billion in 2025 to $12.36 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 1.6%. Historically, factors contributing to this growth include the approval of Lucentis and Eylea, an increase in the prevalence of age-related macular degeneration, a rising incidence of diabetic retinopathy, progress in molecular biology concerning angiogenesis inhibition, and the expansion of ophthalmology services in hospitals.
The anti-vascular endothelial growth factor therapeutics market size is anticipated to experience consistent expansion over the coming years. By 2030, it is projected to reach $13.59 billion, demonstrating a compound annual growth rate (CAGR) of 2.4%. This anticipated growth during the forecast period can be attributed to several factors, including the introduction of next-generation anti-VEGF therapeutics, increased investment in precision oncology, the expanding penetration of the biosimilar market, rising healthcare expenditure in emerging markets, and the adoption of combination therapies in retinal diseases. Furthermore, major trends foreseen in this period involve the growing utilization of anti-VEGF therapies in ophthalmology, the expansion of targeted cancer treatments, the development of biosimilar anti-VEGF drugs, a rising geriatric population driving AMD treatments, and the proliferation of outpatient and specialty clinics.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp
Which Market Drivers Are Supporting The Expansion Of The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The expanding occurrence of ophthalmic diseases is anticipated to fuel the growth of the anti-vascular endothelial growth factor therapeutics market moving ahead. The term “prevalence of ophthalmic diseases” denotes the count or percentage of individuals within a given population who have been identified with or exhibit specific eye conditions or ailments. Anti-vascular endothelial growth factor (VEGF) therapeutics are effective in decreasing the incidence of ophthalmic diseases by providing treatment for conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For instance, data from August 2023, provided by the World Health Organization, a Switzerland-based international public health organization, indicated that approximately 2.2 billion people globally experience near or distance vision impairment, with 1 billion people suffering from near or distance vision impairment. Moreover, among these, 88.4 million are affected by refractive error, 94 million by cataracts, 8 million by age-related macular degeneration, and around 3.9 million by diabetic retinopathy. Consequently, the rising prevalence of ophthalmic diseases is driving the growth of the anti-vascular endothelial growth factor therapeutics market.
What Segmentation Levels Are Considered In The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
What Trends Are Projected To Affect The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Leading companies in the anti-VEGF therapeutics market are increasingly forging strategic alliances to hasten the development, commercialization, and uptake of VEGF inhibitors. These collaborations enable firms to capitalize on complementary skills, access pioneering technologies, and expand their market reach. For example, in January 2025, Teva Pharmaceuticals International GmbH, a Switzerland-based subsidiary of Teva Pharmaceutical Industries focused on biosimilars and complex generics, initiated a strategic partnership with Klinge Biopharma GmbH and Formycon AG to commercialize FYB203, a biosimilar candidate for Eylea (aflibercept), in Europe (excluding Italy) and Israel. Within this collaboration, Teva utilizes its existing commercial infrastructure and distribution channels to enhance its standing in the anti-VEGF therapeutics market. Formycon AG is responsible for the development of FYB203, and Klinge Biopharma GmbH possesses the exclusive global commercialization rights for the product.
Which Leading Firms Are Contributing To The Growth Of The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market are F. Hoffmann-La Roche AG, Pfizer Inc., Coherus BioSciences Inc., Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Allergan Inc., Novartis AG, Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited
Read the full anti-vascular endothelial growth factor therapeutics market report here:
How Is The Anti-Vascular Endothelial Growth Factor Therapeutics Market Distributed Across Key Geographic Regions?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2025. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Anti-Vascular Endothelial Growth Factor Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10683&type=smp
Browse Through More Reports Similar to the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market 2026, By The Business Research Company
Anti Vascular Endothelial Growth Factor Therapeutics Market Report 2026
Tumor Necrosis Factor Inhibitor Drugs Market Report 2026
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model